Welcome to our dedicated page for Maze Therapeutics SEC filings (Ticker: MAZE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Maze Therapeutics, Inc. (Nasdaq: MAZE) SEC filings page brings together the company’s public regulatory disclosures, offering a detailed view of how this clinical-stage biopharmaceutical company reports its activities to U.S. regulators. Maze focuses on small molecule precision medicines for kidney and metabolic diseases, and its filings provide context on both its scientific programs and its capital markets activity.
Maze’s filings include current reports on Form 8-K, which the company uses to announce material events such as quarterly financial results, leadership changes, and financing transactions. For example, Maze has filed 8-Ks to furnish press releases on second and third quarter financial results, to disclose an oversubscribed private placement of common stock and pre-funded warrants, and to document the appointments of a new chief financial officer and a new chairman of the board.
Investors can also review registration statements, such as the company’s Form S-1, which describes Maze’s business, risk factors, and the resale of shares issued in its 2025 private placement. The S-1 outlines Maze’s focus on human genetics, its Compass platform, and its lead programs MZE829 and MZE782, while also confirming its status as an emerging growth company and smaller reporting company.
Through Stock Titan, these filings are updated in near real time from the SEC’s EDGAR system, and AI-powered summaries help explain the key points of lengthy documents. Users can quickly understand what a particular 8-K, S-1, or other filing means for the company without reading every page. Where applicable, filings related to equity financings, registration rights, and governance changes are highlighted so investors can track dilution, board composition, and executive appointments.
For MAZE, monitoring SEC filings is especially relevant for understanding clinical development disclosures, financing capacity, and risk factors associated with its kidney and metabolic disease programs. This page serves as a central resource for reviewing those official documents alongside concise AI-generated explanations.
Maze Therapeutics, Inc. reported a Q1 2026 net loss of $24.2 million, narrower than the $32.8 million loss a year earlier, as it recorded $20.0 million of license revenue from a Shionogi milestone. Operating expenses rose to $46.6 million, driven by higher research and development and general and administrative costs.
The company ended March 31, 2026 with $362.9 million in cash, cash equivalents and marketable securities and had an accumulated deficit of $513.8 million. In February 2026 it put in place a $200.0 million at-the-market equity program and a Hercules term loan facility of up to $200.0 million, funding an initial $40.0 million tranche.
Maze is advancing two wholly owned clinical programs. MZE829, an APOL1 inhibitor for APOL1-mediated kidney disease, delivered positive Phase 2 proof-of-concept data and is being prepared for pivotal development. MZE782 showed favorable Phase 1 results, with Phase 2 trials in phenylketonuria and chronic kidney disease planned for 2026.
Maze Therapeutics reported first quarter 2026 results alongside important clinical and financing updates. The company generated $20.0 million in license revenue from a milestone tied to its MZE001 partnership, while R&D and G&A expenses rose to $34.1 million and $12.4 million, respectively.
Net loss narrowed to $24.2 million, or $0.45 per share, from $32.8 million, or $1.15 per share, a year earlier. Cash, cash equivalents and marketable securities were $362.9 million as of March 31, 2026, and the company highlighted a strong balance sheet of $528 million including April financing and milestone proceeds, supporting an expected cash runway into 2029.
Clinically, Maze reported positive topline Phase 2 HORIZON data for MZE829 in APOL1-mediated kidney disease, showing meaningful reductions in proteinuria and no serious treatment-related adverse events, and it plans a pivotal trial in moderate AMKD without diabetes. Phase 2 proof-of-concept trials for MZE782 in PKU and CKD are planned to initiate in 2026.
Maze Therapeutics, Inc. is filing a post-effective amendment that converts its Prior Registration Statement into a Form S-3 and keeps on registration for resale up to 9,231,092 shares of common stock. The registered shares consist of 4,000,002 Initial Shares and up to 5,231,090 Warrant Shares issuable upon exercise of pre-funded warrants. The registration relates solely to resale by the identified selling stockholders; Maze will not receive proceeds from sales under this prospectus. The prospectus states the Selling Stockholders may sell the Shares at any time, at market or negotiated prices, through underwriters, brokers or private transactions, and will bear underwriting fees and transfer taxes. The company disclosed a last reported sale price of $25.52 per share as of May 11, 2026.
Maze Therapeutics, Inc. Chief Business and Strategy Officer Atul Dandekar exercised stock options to acquire a total of 14,305 shares of Common Stock on May 4, 2026. The options were exercised at an exercise price of $10.42 per share.
Following these transactions, Dandekar directly holds 24,808 shares of Common Stock. The exercised options relate to awards that vest monthly over 48 months, with one award noted as having become fully vested on February 1, 2026, subject to continued service conditions described in the award agreements.
Maze Therapeutics, Inc. director Charles J. Homcy reported a bona fide gift transfer of 7,422 shares of common stock on May 4, 2026. The gift was made for no consideration and is described as exempt under Rule 16b-5. After the transaction, Homcy directly holds 31,113 shares of Maze Therapeutics common stock, a total that includes shares previously held by the Charles J. Homcy Revocable Trust UA 11/4/1998.
Maze Therapeutics, Inc. chief business officer Atul Dandekar exercised stock options for 7,500 shares of common stock at $10.42 per share and on the same day sold 7,500 shares in an open-market transaction at a weighted average price of $25.3732 per share. Following these transactions, he directly holds 10,503 shares of Maze common stock. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan, indicating the timing was set in advance rather than decided opportunistically.
Maze Therapeutics is asking stockholders to attend a virtual 2026 annual meeting on June 8, 2026 to elect two Class I directors, Jason Coloma and Neil Kumar, and to ratify Ernst & Young LLP as independent auditor for the year ending December 31, 2026.
The proxy describes Maze’s clinical-stage focus on genetic precision medicines, its classified, majority‑independent board and committee structure, and non‑employee director pay in cash and stock options. It details 2025 executive pay, including CEO Jason Coloma’s $3.46 million in total compensation, change‑in‑control severance protections, equity plans, major investors, and recent $75 million preferred financing and $141.3 million private placement.
Maze Therapeutics, Inc. entered into an underwriting agreement with Leerink Partners LLC for a registered public offering of 5,540,000 shares of common stock at $23.50 per share and pre-funded warrants to purchase 850,000 shares at $23.499 per warrant. The company expects gross proceeds of $150 million and estimates net proceeds of about $144.7 million after fees and expenses.
The pre-funded warrants carry a $0.001 per share exercise price and are exercisable any time, subject to beneficial ownership caps generally at 4.99% or 9.99%, adjustable up to 19.99% with advance notice. Maze plans to use the funds primarily to advance its clinical-stage programs MZE829 for APOL1-mediated kidney disease and MZE782 for phenylketonuria and chronic kidney disease, and for general corporate purposes. The company states that, with these proceeds and existing cash and investments, it expects to fund operations into 2029.